TPGS1: A Promising Drug Target and Biomarker for Polyglutamylase Subunit 1-Positive Chronic Kidney Disease

Target Name: TPGS1

NCBI ID: G91978

TPGS1

TPGS1: A Promising Drug Target and Biomarker for Polyglutamylase Subunit 1-Positive Chronic Kidney Disease

Introduction

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide, affecting over 10 million people in the United States alone. The progressive loss of kidney function due to CKD can be a challenging and irreversible process, leading to a significant impact on patients' quality of life and overall health. Although there are several treatments available for managing CKD, the development of new therapeutic approaches remains a promising direction in the field. One promising candidate for drug targeting and biomarker identification is TPGS1, a protein expressed in the urine and plasma of individuals with polyglutamylase subunit 1 (PGLUT1) deficiency.

In this article, we will explore the biology and pathology of PGLUT1 and TPGS1, as well as the potential implications of TPGS1 as a drug target and biomarker for PGLUT1-positive CKD.

The biology and pathology of PGLUT1 and TPGS1

PGLUT1 is a single-chain protein that belongs to the family of glutamyltransferases (GTTs). PGLUT1 is responsible for the transfer of glutamyl groups from the amino acids Asp and Glu to ubiquitin, polyamine and sulfate groups, modified Ubiquitin can activate a series of signaling pathways, including cell cycle, cell proliferation, apoptosis and immune response. The activity of PGLUT1 is affected by a variety of regulatory factors, including DNA damage, oxidative stress, cytokines and inflammation.

PGLUT1 deficiency can lead to a variety of diseases and pathological conditions, including neuropsychiatric diseases, tumors, cardiovascular diseases, and renal diseases. In kidney diseases, the activity of PGLUT1 is affected by a variety of pathological factors, such as damage to renal tubular epithelial cells, oxidative stress, inflammation and fibrosis. Activation of PGLUT1 can lead to damage and dysfunction of renal tubular epithelial cells, increase protein loss in renal tubular fluid, and then lead to renal tubular dysfunction and renal insufficiency.

TTGS1 is a glycoprotein composed of two subunits, including N-terminal 伪-helix and C-terminal 尾-sheet. TTGS1 is expressed in urine and plasma and plays an important role in a variety of diseases, such as renal tubular epithelial cell injury, urinary tract infection, liver disease and tumors. Activation of TTGS1 can lead to a variety of pathological changes, including cell proliferation, apoptosis, inflammation, and fibrosis.

The pathological effects of TTGS1 are closely related to the multiple signaling pathways it activates. Activation of TTGS1 can lead to prolonged S phase and G2 phase in the cell cycle, increasing the possibility of cell proliferation. At the same time, activation of TTGS1 can induce apoptosis and promote cell death. Activation of TTGS1 can also cause oxidative stress and inflammatory responses, aggravating the development of kidney disease.

Pharmacological significance of TTGS1

As a new target, TTGS1 has great potential in drug research and development. Currently, TTGS1 has been used in the treatment of a variety of diseases, including renal tubular epithelial cell damage, urinary tract infections, liver diseases and tumors. TTGS1 inhibitors can inhibit the activity of TTGS1, thereby reducing pathological effects, improving renal function, and reducing patient mortality.

As a drug target, TTGS1 has a variety of pharmacological properties. TTGS1 is expressed in urine and plasma and is not easily modified, so it has good pharmacokinetic properties. Activation of TTGS1 can lead to a variety of pathological changes, including cell proliferation, apoptosis, inflammation, and fibrosis, and therefore has a variety of biological effects. TTGS1 inhibitors can inhibit the activity of TTGS1, thereby inhibiting a variety of pathological changes and have a wide range of pharmacological effects.

As a biomarker, TTGS1 has various application values. The activity of TTGS1 can be used as an indicator to monitor the damage and function of renal tubular epithelial cells, and can also be used as an important indicator to evaluate the severity and prognosis of various kidney diseases. TTGS1 activity may also serve as a potential biomarker for drug efficacy and disease progression.

Protein Name: Tubulin Polyglutamylase Complex Subunit 1

Functions: Subunit of the tubulin polyglutamylase complex (TPGC). The complex mediates cilia and flagella polyglutamylation which is essential for their biogenesis and motility (Probable). May act in the targeting of the tubulin polyglutamylase complex. Required for the development of the spermatid flagellum (By similarity)

The "TPGS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TPGS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets